Cited by 770Hepatitis C virus researchLiver physiology and pathologyLiver Disease Diagnosis and Treatment

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Hepatitis C: the clinical spectrum of disease.

Open access

Hoofnagle, J H·1997·Hepatology

Open this paper in CoChat — free account Open PDF

Abstract

Hepatitis C virus (HCV) accounts for approximately 20% of cases of acute hepatitis, 70% of chronic hepatitis, and 30% of end-stage liver disease in the United States. The acute infection has an incubation period of 7 weeks (range, 4-20 weeks) and is symptomatic and icteric in only one third of patients. Serum aminotransferase levels generally increase greater than 10-fold elevated and as symptoms and signs resolve decrease into the normal range. Antibody to HCV is usually but not always present at the time of onset of symptoms. HCV RNA appears in the serum early during the incubation period, increases in titer and peaks at the time of symptoms, and then disappears in resolving disease. Importantly, 85% of patients with acute HCV infection develop chronic infection. In these patients, HCV RNA remains present and in approximately two thirds of patients, aminotransferases remain elevated in the range of 1.5- to 10-fold the upper limit of normal. The course of chronic hepatitis C is variable. Probably fewer than 20% of patients have symptoms and they are usually intermittent, vague, and nonspecific, largely being malaise and easy fatiguability. A small percentage of patients develop extrahepatic manifestations of hepatitis C, including cryoglobulinemia and glomerulonephritis. It is estimated that 20% to 30% of patients with chronic hepatitis C develop cirrhosis, but the process is generally slow and insidious. Once cirrhosis develops, symptoms are more common and the signs of end-stage liver disease can appear with jaundice, weakness, wasting, and gastrointestinal bleeding. Patients with cirrhosis are also at risk for developing hepatocellular carcinoma. Thus, this important liver disease has protean manifestations but is often insidious and can lead to end-stage liver disease despite the presence of few symptoms and signs of illness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.510260703

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M. A., Hoofnagle, J. H., Manns, M. P., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,591
Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis
Alter, H. J., Purcell, R. H., Shih, J. W., Melpolder, J. C., Houghton, M., Choo, Q.-L., & Kuo, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212202 · Cited by 1,658
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,191
Long-Term Outcome of Hepatitis C Infection after Liver Transplantation
Gane, E. J., Portmann, B. C., Naoumov, N. V., Smith, H. M., Underhill, J. A., Donaldson, P. T., Maertens, G. G., & Williams, R. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603283341302 · Cited by 963
Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection
Johnson, R. J., Gretch, D. R., Yamabe, H., Hart, J., Bacchi, C. E., Hartwell, P., Couser, W. G., Corey, L., Wener, M. H., Alpers, C. E., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280703 · Cited by 870
Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease
Houghton, M., Weiner, A. J., Han, J. H., Kuo, G. C., & Choo, Q. (1991) · Hepatology · doi:10.1002/hep.1840140227 · Cited by 862
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Weiner, A. J., Geysen, H. M., Christopherson, C., Hall, J. E., Mason, T. J., Saracco, G. M., Bonino, F., Crawford, K., Marion, C. D., & Crawford, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3468 · Cited by 703
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell‐Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 668
PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Colombo, M., Choo, Q. L., Ninno, E. D., Dioguardi, N., Kuo, G. C., Donato, M. F., Tommasini, M., & Houghton, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91016-7 · Cited by 666
Routes of Infection, Viremia, and Liver Disease in Blood Donors Found to Have Hepatitis C Virus Infection
Conry‐Cantilena, C., VanRaden, M. J., Gibble, J. W., Melpolder, J. C., Shakil, A. O., Viladomiu, L., Cheung, L., DIBISCEGLIE, A., Hoofnagle, J. H., Shih, J. W., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342602 · Cited by 627

Show all 47 references

Research works printed but not linked: 6

Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
Barrera JM, Bruguera M, Guadalupe-Ercilla M, Gil C, Celis R, Gil MP, del Valle Onorato M, et al. Persistent hepatitis C viremia after acute HEPATOLOGY 1995;21:725-729.
Morales TG, Sampliner RE, Bhattacharyya A, Alter MJ. Liver histology self-limiting posttransfusion hepatitis C. HEPATOLOGY 1995;21:639-644.
Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, Miller in anti-HCV positive persons with normal or minimally elevated amino- transferases. J Clin Gastroenterol 1995;21:301-305.
Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Don- 1995;123:897-903.

Sorted by citations

Items 201–300 of 770

Prospective Comparison of Whole-Blood- and Plasma-Based Hepatitis C Virus RNA Detection Systems: Improved Detection Using Whole Blood as the Source of Viral RNA
Stapleton, J. T., Klinzman, D., Schmidt, W. N., Pfaller, M. A., Wu, P., LaBrecque, D. R., Han, J.-Q., Phillips, M. J. P., Woolson, R. F., & Alden, B. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.484-489.1999 · Cited by 49
Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine
Elottol, A. E., Elmanama, A. A., & Ayesh, B. M. (2010) · Virology Journal · doi:10.1186/1743-422x-7-210 · Cited by 51
Inhibition of hepatitis C virus replication and internal ribosome entry site-dependent translation by an RNA molecule
Romero‐López, C., Díaz-González, R., Jesus, A. B.-D., & Berzal‐Herranz, A. (2009) · Journal of General Virology · doi:10.1099/vir.0.008821-0 · Cited by 50
Ribavirin monotherapy for chronic hepatitis C
Brok, J. S., Gluud, L. L., & Gluud, C. N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005527.pub2 · Cited by 49
Helicobacter pylori and Hepatitis C virus coinfection in Egyptian patients
El-Shahat, M., El-Masry, S. A., Badra, G., Aboel-Nour, M., & Lotfy, M. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.59244 · Cited by 49
Co-infecção HIV e vírus da hepatite B: prevalência e fatores de risco
de Souza, M. G., Passos, A. D. C., Machado, A. A., Figueiredo, J. F. D. C., & Esmeraldino, L. E. (2004) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/s0037-86822004000500004 · Cited by 49
Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease
Anand, B. S. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i16.2409 · Cited by 49
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease.
Vecchiet, J., Falasca, K., Cacciatore, P., Zingariello, P., Dalessandro, M., Marinopiccoli, M., D'Amico, E., Palazzi, C., Petrarca, C., Conti, P., et al. (2005) · PubMed · Cited by 49
Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b
Neri, S., Bruno, C. M., Abate, G., Ierna, D., Mauceri, B., Cilio, D., Bordanaro, F., Pulvirenti, D., Claudio, I., & Caruso, L. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80065-0 · Cited by 49
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels
Alberti, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.004 · Cited by 49
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
Gerotto, M., Pero, F. D., Bortoletto, G., Ferrari, A., Pistis, R., Sebastiani, G., FAGIUOLI, S., Realdon, S., & Alberti, A. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.08.016 · Cited by 49
Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures
George, S. L., Xiang, J., & Stapleton, J. T. (2003) · Virology · doi:10.1016/s0042-6822(03)00585-3 · Cited by 48
Population-based hepatitis C surveillance and treatment in a national managed care organization.
Shatin, D., Schech, S. D., Patel, K., & McHutchison, J. G. (2004) · PubMed · Cited by 48
Prevention of hepatitis C virus infection*
Kew, M. C., François, G., Lavanchy, D., Margolis, H. S., Damme, P. V., Grob, P. J., Hallauer, J. F., Shouval, D., Leroux-Roels, G. G., & Meheus, A. (2004) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2004.00492.x · Cited by 48
C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle
Kinast, V., Płóciennikowska, A., Anggakusuma, Bracht, T., Tödt, D., Brown, R. J. P., Boldanova, T., Zhang, Y., Brüggemann, Y., Friesland, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.047 · Cited by 47
Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
Jarczak, D., Korf, M., Beger, C., Manns, M. P., & Krüger, M. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04986.x · Cited by 47
Association between Hepatitis C Virus Infection and Diabetes Mellitus
Mehta, S. H., Strathdee, S. A., & Thomas, D. L. (2001) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a000808 · Cited by 47
Interferon-alpha (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway
Kaser, A., Enrich, B., Ludwiczek, O., Vogel, W., & Tilg, H. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.01020.x · Cited by 47
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
Younossi, Z. M., Mullen, K. D., Zakko, W. F., Hodnick, S., Brand, E., Barnes, D. S., Carey, W. D., McCullough, A. C., Easley, K. A., Boparai, N., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00003-9 · Cited by 47
Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview
El‐Shamy, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7555 · Cited by 46
New Animal Models of Hepatitis B and C
Feitelson, M. A., & Larkin, J. D. (2001) · ILAR Journal · doi:10.1093/ilar.42.2.127 · Cited by 46
Treatment with silybin‐vitamin E‐phospholipid complex in patients with hepatitis C infection
Falasca, K., Ucciferri, C., Mancino, P., Vitacolonna, E., Tullio, D. D., Pizzigallo, E., Conti, P., & Vecchiet, J. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21292 · Cited by 45
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
Schmidt, W. N., & Kayali, Z. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52629 · Cited by 45
Stability of HCV‐RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers
Yeo, A. E. T., Ghany, M. G., Conry‐Cantilena, C., Melpolder, J. C., Kleiner, D. E., Shih, J. W., Hoofnagle, J. H., & Alter, H. J. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00302.x · Cited by 45
Strain-Specific T-Cell Suppression and Protective Immunity in Patients with Chronic Hepatitis C Virus Infection
Sugimoto, K., Kaplan, D. E., Ikeda, F., Ding, J. W., Schwartz, J., Nunes, F. A., Alter, H. J., & Chang, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.6976-6983.2005 · Cited by 45
Hepatitis C and liver transplantation.
Tsoulfas, G., Goulis, I., Giakoustidis, D. E., Akriviadis, E. A., Agorastou, P., Imvrios, G., & Papanikolaou (2009) · PubMed Central · Cited by 44
Expression of Gastrointestinal Glutathione Peroxidase Is Inversely Correlated to the Presence of Hepatitis C Virus Subgenomic RNA in Human Liver Cells
Morbitzer, M., & Herget, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m413730200 · Cited by 44
Hepatitis C Virus Core Protein Acts as a trans-Modulating Factor on Internal Translation Initiation of the Viral RNA
Boni, S., Lavergne, J.-P., Boulant, S., & Cahour, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501826200 · Cited by 44
Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil
Silva, L. K., Silva, M. B., Rodart, I. F., Lopes, G. B., Costa, F. Q., de Melo, M. E. L., Gusmão, E., & dos Reis, M. G. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000500005 · Cited by 44
Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
Rumi, M. G., Filippi, F. D., Donato, M. F., Ninno, E. D., & Colombo, M. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00328.x · Cited by 44
Treatment for Hepatitis C Virus in Human Immunodeficiency Virus–Infected Patients
Kuehne, F., Bethe, U., Freedberg, K. A., & Goldie, S. J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2545 · Cited by 44
Overexpression of Hepatitis C Virus NS5A Protein Induces Chromosome Instability via Mitotic Cell Cycle Dysregulation
Baek, K., Park, H.-Y., Kang, C., Kim, S., Jeong, S.-J., Hong, E.-K., Park, J., Sung, Y., Suzuki, T., Kim, C., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.03.020 · Cited by 46
Hepatitis C virus (HCV) NS5A protein downregulates HCV IRES-dependent translation
Kalliampakou, K. I., Kalamvoki, M., & Mavromara, P. (2005) · Journal of General Virology · doi:10.1099/vir.0.80728-0 · Cited by 43
Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT
Jacobson, I. M., Ahmed, F., Russo, M. W., Lebovics, E., Dieterich, D. T., Esposito, S. P., Bach, N., Klion, F. M., Tobias, H., Antignano, L. V., et al. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30049.x · Cited by 43
Hepatitis C virus genotypes in a northeastern area of Brazil.
Silva, L. K., Paraná, R., de Souza, S. P., Berby, F., Kay, A., TREPO, C. G., Santana, N., Cotrim, H. P., Lyra, L. G. C., & dos Reis, M. G. (2000) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2000.62.257 · Cited by 43
Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C
Layden, T. J., Layden, J. E., Reddy, K. R., Levy‐Drummer, R. S., Poulakos, J. J., & Neumann, A. U. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00376.x · Cited by 43
Health state utilities associated with attributes of treatments for hepatitis C
Matza, L. S., Sapra, S. J., Dillon, J. F., Kalsekar, A., Davies, E. W., Devine, M. K., Jordan, J. B., Landrian, A. S., & Feeny, D. H. (2014) · The European Journal of Health Economics · doi:10.1007/s10198-014-0649-6 · Cited by 42
Persistent RNA virus infections: do PAMPS drive chronic disease?
McCarthy, M. K., & Morrison, T. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.01.003 · Cited by 42
Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients
Shores, N. J., Maida, I. R., Soriano, V., & Núñez, M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.04.010 · Cited by 42
Increased risk of chronic hepatitis in children with cancer
Sevinir, B., Meral, A., Günay, Ü., Özkan, T., Özuysal, S., & Sinirtas, M. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.10090 · Cited by 42
Increased prooxidant production and enhanced susceptibility to glutathione depletion in HepG2 cells co‐expressing HCV core protein and CYP2E1
Wen, F., Abdalla, M. Y., Aloman, C., Xiang, J., Ahmad, I. M., Walewski, J. L., McCormick, M. L., Brown, K. E., Branch, A. D., Spitz, D. R., et al. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10567 · Cited by 42
Acute hepatitis C complicated by pancreatitis: another extrahepatic manifestation of hepatitis C virus?
Álvares‐da‐Silva, M. R., Francisconi, & Waechter (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00176.x · Cited by 41
Hepatitis C: an update
Moradpour, D., Cerny, A., Heim, M. H., & Blum, H. E. (2001) · Swiss Medical Weekly · doi:10.4414/smw.2001.06097 · Cited by 41
Developments in the treatment of chronic hepatitis C
Pockros, P. J. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.4.515 · Cited by 41
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy
Querenghi, F., Qiang, Y., Billaud, G., Maertens, G. G., TREPO, C. G., & Zoulim, F. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00265.x · Cited by 41
Medical chlamydiology--a position paper.
Mårdh, P. A. (1982) · PubMed · Cited by 40
Hepatocyte-derived microRNAs as sensitive serum biomarkers of hepatocellular injury in Labrador retrievers
Dirksen, K., Verzijl, T., van den Ingh, T. S. G. A. M., Vernooij, J. C. M., van der Laan, L. J. W., Burgener, I. A., Spee, B., & Fieten, H. (2016) · The Veterinary Journal · doi:10.1016/j.tvjl.2016.01.010 · Cited by 40
Hepatitis C databases, principles and utility to researchers
KUIKEN, C. L., Mizokami, M., Deléage, G., Yusim, K., Pénin, F., Shin-I, T., Charavay, C., Tao, N., Crisan, D., Grando, D., et al. (2006) · Hepatology · doi:10.1002/hep.21162 · Cited by 40
Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3
Yu, H. B., Babiuk, L. A., & den Hurk, S. V. D. L. (2004) · Journal of General Virology · doi:10.1099/vir.0.79821-0 · Cited by 39
Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells
Balasubramanian, A., Munshi, N., Koziel, M. J., Hu, Z., Liang, T. J., Groopman, J. E., & Ganju, R. K. (2005) · Journal of General Virology · doi:10.1099/vir.0.81056-0 · Cited by 39
Liver Biopsy Findings for HIV‐Infected Patients with Chronic Hepatitis C and Persistently Normal Levels of Alanine Aminotransferase
Sánchez‐Conde, M., Berenguer, J., Miralles, P., Alvarez, F., López, J. C., Cosín, J., Pilar, C., Ramírez, M., Gutiérrez, I., & Álvarez, E. (2006) · Clinical Infectious Diseases · doi:10.1086/506440 · Cited by 39
A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37
MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection
Gentile, I., Buonomo, A. R., Borgia, F., Zappulo, E., Castaldo, G., & Borgia, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.902049 · Cited by 38
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
Gentile, I., Buonomo, A. R., Zappulo, E., Minei, G., Morisco, F., Borrelli, F., Coppola, N., & Borgia, G. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s66731 · Cited by 38
Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users
Alavian, S. M., Mirahmadizadeh, A., Javanbakht, M., Keshtkaran, A., Heidari, A., Mashayekhi, A., Salimi, S., & Hadian, M. R. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.12411 · Cited by 38
Liver disease in Viet Nam: Screening, surveillance, management and education: A 5‐year plan and call to action
Gish, R. G., Bui, T. D., Nguyen, C. T. K., Nguyen, D. T., Tran, H. V., Tran, D., Trinh, H. N., & International Group for Liver Health in Viet Nam (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06974.x · Cited by 38
Recombinant hepatitis C virus‐like particles expressed by baculovirus: Utility in cell‐binding and antibody detection assays
Xiang, J., Wünschmann, S., George, S. L., Klinzman, D., Schmidt, W. N., LaBrecque, D. R., & Stapleton, J. T. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10237 · Cited by 39
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
Wong, J. B., Davis, G. L., & Pauker, S. G. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00303-x · Cited by 38
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
Gentile, I., Coppola, N., Buonomo, A. R., Zappulo, E., & Borgia, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.921680 · Cited by 37
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
Evon, D. M., Stewart, P. W., Amador, J., Serper, M., Lok, A. S.-F., Sterling, R. K., Sarkar, S., Golin, C. E., Reeve, B. B., Nelson, D. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196908 · Cited by 37
The hepatitis C virus NS2/3 protease.
Welbourn, S., & Pause, A. (2007) · PubMed · Cited by 37
Th1 Disabled Function in Response to TLR4 Stimulation of Monocyte-Derived DC from Patients Chronically-Infected by Hepatitis C Virus
Perrin‐Cocon, L., Agaugué, S., Diaz, O., Vanbervliet, B., Dollet, S., Guironnet‐Paquet, A., André, P., & Lotteau, V. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002260 · Cited by 37
Urinary Screening for Detection of Renal Abnormalities in Asymptomatic School Children
Parakh, P., Bhatta, N. K., Mishra, O. P., Shrestha, P. K., Budhathoki, S., Majhi, S., Sinha, A. K., Dhungel, K., Prabhakar, R., & Haldhar, N. (2012) · Nephro-Urology Monthly · doi:10.5812/numonthly.3528 · Cited by 37
Current and future hepatitis C virus diagnostic testing: problems and advancements
Majid, A., & Gretch, D. R. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)01650-7 · Cited by 37
Stereoselective Synthesis and Biological Evaluations of Novel 3′-Deoxy-4′-azaribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication
Chiacchio, U., Borrello, L., Crispino, L., Rescifina, A., Merino, P., Macchi, B., Balestrieri, E., Mastino, A., Piperno, A., & Romeo, G. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900197j · Cited by 36
Hepatitis C virus diagnosis and testing.
Krajden, M. (2000) · PubMed · Cited by 36
Prevalence and Clinical Spectrum of Chronic Viral Hepatitis in a Middle-aged Swedish General Urban Population
Hoffmann, G. (2000) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655200750023246 · Cited by 36
Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence
Lanford, R. E., Lee, H., Chavez, D., Guerra, B., & Brasky, K. M. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-6-1291 · Cited by 36
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C
Coppola, N., Gentile, I., Pasquale, G. D., Buonomo, A. R., Capoluongo, N., D'Armiento, M. R., Borgia, G., & Sagnelli, E. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30900-7 · Cited by 35
Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy
Li, S., Yu, X., Guo, Y., & Kong, L. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2012.01773.x · Cited by 35
Alcohol Consumption Decisions Among Nonabusing Drinkers Diagnosed with Hepatitis C
Stoller, E. P., Webster, N. J., Blixen, C. E., McCormick, R. A., Hund, A. J., Perzynski, A. T., Kanuch, S. W., Thomas, C. L., Kercher, K., & Dawson, N. V. (2008) · Journal of Mixed Methods Research · doi:10.1177/1558689808326119 · Cited by 35
Autophagy in hepatitis C virus-host interactions: Potential roles and therapeutic targets for liver-associated diseases
Ke, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i19.5773 · Cited by 35
In Vitro Interaction between Hepatitis C Virus (HCV) Envelope Glycoprotein E2 and Serum Lipoproteins (LPs) Results in Enhanced Cellular Binding of Both HCV E2 and LPs
Wünschmann, S., Müller, H. M., Stipp, C. S., Hemler, M. E., & Stapleton, J. T. (2006) · The Journal of Infectious Diseases · doi:10.1086/507647 · Cited by 35
Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses
Re, V. D., Vita, S. D., Sansonno, D. E., Gasparotto, D., Simula, M. P., Tucci, F. A., Marzotto, A., Fabris, M., Gloghini, A., Carbone, A., et al. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kei278 · Cited by 35
Medicinal herbs for hepatitis C virus infection
Liu, J., Manheimer, E. W., Tsutani, K., & Gluud, C. N. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003183 · Cited by 34
The impact of hepatitis C virus infection on methadone maintenance treatment.
Novick, D. M. (2000) · PubMed · Cited by 35
Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b
Takacs, C. N., Andréo, U., Thi, V. L. D., Wu, X., Gleason, C. E., Itano, M. S., Spitz, G. S., Belote, R. L., Hedin, B. R., Scull, M. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.053 · Cited by 34
The beta hairpin structure within ribosomal protein S5 mediates interplay between domains II and IV and regulates HCV IRES function
Bhat, P., Shivaprasad, S., Sharma, D. K., Joseph, A. P., Srinivasan, N., & Das, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv110 · Cited by 34
Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury
Ciccaglione, A. R., Marcantonio, C., Tritarelli, E., Equestre, M., Vendittelli, F., Costantino, A., Geraci, A., & Rapicetta, M. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.006 · Cited by 34
Suppression of hepatitis C virus replication by protein kinase C‐related kinase 2 inhibitors that block phosphorylation of viral RNA polymerase
Kim, S. ‐., Kim, J. H., Sun, J.-M., Kim, M. ‐., & Oh, J. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01108.x · Cited by 34
Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA
Macejak, D. G., Jensen, K. L., Pavco, P. A., Phipps, K., Heinz, B. A., Colacino, J. M., & Blatt, L. M. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00321.x · Cited by 34
Natural History and Disease Manifestations of Hepatitis C Infection
Theodore, D., & Fried, M. W. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59605-6_3 · Cited by 34
Hepatitis c virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics
Prakash, O. (2002) · Frontiers in bioscience · doi:10.2741/a924 · Cited by 34
Polypyrimidine tract-binding protein (PTB) inhibits Hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation, but does not affect HCV replication
Tischendorf, J. J. W., Beger, C., Korf, M., Manns, M. P., & Kr�ger, M. (2003) · Archives of Virology · doi:10.1007/s00705-004-0341-8 · Cited by 33
Induction of intercellular adhesion molecule 1 gene expression by measles virus in human umbilical vein endothelial cells
Harcourt, B. H., Rota, P. A., Hummel, K. B., Bellini, W. J., & Offermann, M. K. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199901)57:1 · Cited by 23
Immune-mediated myelitis associated with Hepatitis virus infections
Stübgen, J. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.09.001 · Cited by 32
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment
Park, S., & Hahn, Y. S. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0032 · Cited by 35
Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities
Mbaeyi, C., & Thompson, N. D. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12097 · Cited by 32
Fatigue Complicating Chronic Liver Disease
Jones, E. A. (2004) · Metabolic Brain Disease · doi:10.1023/b:mebr.0000043986.70972.3b · Cited by 32
Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level.
Yates, S. C., Hafez, M. T., Beld, M., Lukashov, V. V., Hassan, Z. K., Carboni, G., Khaled, H. M., McMorrow, M., Attia, M., & Goudsmit, J. (1999) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1999.60.714 · Cited by 32
Hepatitis C advances in antiviral therapy: What is accepted treatment now?
McHutchison, J. G. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02777.x · Cited by 32
A coinfection model for HIV and HCV
Carvalho, A. R. M., & Pinto, C. M. A. (2014) · Biosystems · doi:10.1016/j.biosystems.2014.08.004 · Cited by 31
Expression of Hepatitis C Virus Proteins Does Not Interfere With Major Histocompatibility Complex Class I Processing and Presentation In Vitro
Moradpour, D., Grabscheid, B., Kammer, A. R., Schmidtke, G., Groettrup, M., Blum, H. E., & Cerny, A. (2001) · Hepatology · doi:10.1053/jhep.2001.23793 · Cited by 31
Community Incidence of Hepatitis B and C among Reincarcerated Women
Macalino, G., Vlahov, D., Dickinson, B. P., Schwartzapfel, B., & Rich, J. D. (2005) · Clinical Infectious Diseases · doi:10.1086/432936 · Cited by 30
The Hepatitis C Virus NS2/3 Protease
(2007) · Current Issues in Molecular Biology · doi:10.21775/cimb.009.063 · Cited by 30
A molecular chaperone glucose-regulated protein 94 blocks apoptosis induced by virus infection
Lee, S. H., Song, R., Lee, M. N., Kim, C. S., Lee, H., Kong, Y., Kim, H., & Jang, S. K. (2008) · Hepatology · doi:10.1002/hep.22107 · Cited by 30
The Impact of Rapid Evolution of Hepatitis Viruses
Quer, J., Martell, M., Rodriguez, F., Bosch, A., Jardí, R., Buti, M., & Esteban, J. I. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374153-0.00015-1 · Cited by 30
Aptamer-conjugated magnetic nanoparticles for the efficient removal of HCV particles from human plasma samples
Delaviz, N., Gill, P., Ajami, A., & Aarabi, M. (2015) · RSC Advances · doi:10.1039/c5ra12209k · Cited by 29
Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti‐hepatitis B vaccination
Castellanos, M., Cinza, Z., Guridi, Z. D., Ríos, G. V., Vega, H., Lorenzo, I., Ojeda, S., Dueñas‐Carrera, S., Alvarez‐Lajonchere, L., Martínez, G., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1407 · Cited by 29
Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies
Vos, R. D., Verslype, C., Depla, E., Fevery, J., Damme, B. V., Desmet, V. J., & Roskams, T. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00236-2 · Cited by 29

Authors: Hoofnagle, J. H.
Affiliations: National Institutes of Health (US)
Corresponding author: Hoofnagle, J H
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-12
Volume: 26
Issue: Supplement 3
Pages: 15S-20S
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.510260703
OpenAlex: W1979931682
Cited by: 765
References: 47
Citations by year: 2026: 3 · 2025: 8 · 2024: 11 · 2023: 8 · 2022: 8 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 14 · 2017: 11 · 2016: 25 · 2015: 20 · 2014: 32 · 2013: 26 · 2012: 20
FWCI: 27.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6483 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords: hepatitis C, hepatitis C virus, acute hepatitis C, chronic hepatitis C, end-stage liver disease, liver cirrhosis, hepatocellular carcinoma, extrahepatic manifestations, cryoglobulinemia, glomerulonephritis, aminotransferase elevation, HCV RNA, incubation period, clinical spectrum
MeSH terms: Acute Disease, Transaminases, Chronic Disease, Hepatitis C, Humans, Severity of Illness Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatitis C: the clinical spectrum of disease.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks